Skip to main content
OpenTrials
Completed

NCT Number: NCT04517318

Treatment After Palbociclib-containing Regimens

To evaluate the prescription patterns and treatment outcomes of subsequent therapies after progression on palbociclib in the real world.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • woman, age > 18 years old
  • Diagnosed with HR+/HER2- Metastatic Breast Cancer
  • Patients received at least one-cycle next-line treatment after progression on combined palbociclib and endocrine therapy
  • Complete medical history was available

Exclusion criteria

  • Medical history was incomplete

Treatment and study plan

Primary outcomes

  1. PFS

    Time frame: 6 weeks

    Progression free survival

  2. Adverse events

    Time frame: 6 weeks

    Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

A Multi-center Study of the Treatment Patterns and Clinical Outcomes of Subsequent Therapies After Progression on Palbociclib in HR+/HER2- Metastatic Breast Cancer

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Aug 18, 2020
Registry last updated
Aug 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.